This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
IMAAVY™ (nipocalimab-aahu)
Medical Information
IMAAVY - Dosage in Patients with Warm Autoimmune Hemolytic Anemia
Last Updated: 08/25/2026
Summary
- The company cannot recommend any practices, procedures, or usage of IMAAVY that deviate from the approved labeling.
- Please refer to the local labeling for further information on dosage and administration of IMAAVY for the treatment of warm autoimmune hemolytic anemia (wAIHA).
PRESCRIBING INFORMATION
DOSAGE AND ADMINISTRATION
Recommended Dosage1
- Dilute IMAAVY prior to administration. Administer via intravenous infusion only.
- The recommended initial dosage of IMAAVY is 30 mg/kg administered once via intravenous infusion over at least 30 minutes.
- Four weeks after the initial dose, administer a subsequent dose of 30 mg/kg via intravenous infusion over at least 15 minutes. Continue the subsequent dose every four weeks thereafter.
- If a scheduled infusion is missed, administer the dose of IMAAVY as soon as possible. Resume dosing, maintaining the treatment interval.
References
| 1 | IMAAVY (nipocalimab-aahu) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/IMAAVY-pi.pdf |
Would you like to clear and leave your conversation? Message history will be lost.